[The influence of Daclizumab (Zenapaxe) on the postoperative period in allogenic kidney recipients].
The subjects of the study were 48 patients who were administered Daclizumab (Zenapaxe) immediately after transplantation (main group), and 17 controls. The number of infusions depended on the dynamics of the absolute CD-25 number in the peripheral blood, and varied between 1 and 11. The following variables were measured in order to evaluate the influence of Zenapaxe on the course of the postoperative period: 24-hour proteinuria, blood creatinine, steroid pulse number, blood pressure, and the doses of oral corticosteroids. All the patients were examined before discharge and 1 year after transplantation. Comparative analysis revealed the following: 1. In the main group proteinuria was 1.5 times lower 1 year after surgery vs. its level before discharge, while in the controls proteinuria grew up; 2. Steroid pulses in the controls were 4 times more frequent than this parameter in the main group; 3. Blood pressure and blood creatinine in the main group decreased during the first year after surgery, while in the control group the situation was the opposite. Thus, Zenapaxe (Daclizumab) is an effective immunosuppressive agent, displaying positive influence on the course of the posttransplantation period.
Goriaĭnov
V A
VA
Morozova
M M
MM
Kaabak
M M
MM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D000077561:Daclizumab; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab